Anecortave Acetate Risk Reduction Trial (AART)

PHASE3TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
AMD
Interventions
DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

One 0.5 mL injection into the PJD at 6-month intervals for 42 months

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/mL

One 0.5 mL injection into the PJD at 6-month intervals for 42 months

OTHER

Anecortave Acetate Vehicle

One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.

Trial Locations (1)

76134

India, Bangalore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00332657 - Anecortave Acetate Risk Reduction Trial (AART) | Biotech Hunter | Biotech Hunter